Plain-English translation of NCT06737380 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing UC-MSC cell therapy — a treatment made from cells found in umbilical cord tissue — to see if it can help control lupus and protect kidney function. You would receive a single dose of this cell therapy alongside your regular lupus medications. The study will track how well the treatment works and whether it's safe for lupus patients.
Lupus is a serious autoimmune disease that can damage the kidneys and doesn't always respond well to existing treatments. Researchers hope this cell therapy might reduce lupus activity and help preserve kidney health in patients who need more options.
You likely qualify if…
You likely don't qualify if…
You would receive one dose of the cell therapy injected under your skin, in addition to your current lupus medications. You'll attend regular clinic visits for blood and urine tests, physical exams, kidney imaging, and disease activity assessments to monitor how the treatment affects your lupus. The study will watch carefully for any side effects and track changes in your kidney function and lupus symptoms over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States